The Food and Drug Administration's top drug official is stepping down, marking the latest in a series of leadership changes at the powerful health agency. Dr. Tracy Beth Hoeg, who has been serving as the acting director of the FDA's drug center, will be replaced by Dr. Mike Davis, the current deputy director, according to an internal email obtained by the Associated Press.
Background and Context
Hoeg's departure follows the resignation of FDA Commissioner Dr. Marty Makary earlier this week and the stepping down of Dr. Vinay Prasad, the agency's vaccine and biotech chief, last month. These changes come amid intense criticism from drugmakers, patients, and investors. The agency also announced that Karim Mikhail, a longtime pharmaceutical executive, will take over as acting director of the vaccines center.
Hoeg's Tenure and Controversies
Hoeg, a sports medicine physician and public health scientist, first gained attention during the pandemic as a critic of masking, school closures, and vaccine mandates. She was closely aligned with Makary and Health Secretary Robert F. Kennedy Jr. Her rapid rise through the FDA was engineered by Makary, who promoted her from special assistant to leading the agency's largest center, responsible for regulating most U.S. prescription and over-the-counter drugs. This was unusual, as center directors are typically career scientists with decades of experience; Hoeg had no prior government or management experience.
Since joining the FDA last March, Hoeg led investigations into the safety of injectable RSV drugs for children, antidepressants, and COVID-19 vaccines. These inquiries reflected her longstanding interests and concerns from before joining the government. She co-wrote papers with other medical contrarians, including Makary and Prasad, and frequently expressed her opinions in blog posts and podcasts, including one titled 'Vaccine Curious,' which discussed discredited ideas about mRNA vaccines containing harmful DNA contaminants.
Policy Impact and Legal Challenges
Hoeg was instrumental in the Trump administration's recent effort to drop several federally recommended shots for children, including those for the flu and hepatitis B at birth. These changes have been temporarily blocked by a federal judge in Boston, though the administration plans to appeal. At the FDA, Hoeg led an 'initial analysis' of vaccine injuries that linked COVID-19 shots to 10 reported deaths in children without providing supporting evidence. The findings were discussed in an internal memo sent by Prasad but have not been formally announced or explained. Officials from the FDA and the Centers for Disease Control and Prevention have previously concluded that serious side effects from vaccines are extremely rare.
More recently, Hoeg was involved in a review of a petition to add bold new warnings to antidepressant drugs about unproven pregnancy risks, including fetal abnormalities that could lead to autism. In March, she attempted to hire the petition's author as a senior adviser, raising concerns among staff due to her repeated references to the person as a friend.
Conclusion
Hoeg's exit adds to the ongoing shake-up at the FDA, which has seen key officials leave amid political pressure and internal turmoil. The agency's future direction remains uncertain as new leaders step in.
